Clinical trial
Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed…
NCT00095680 · Scios, Inc., Industry · Completed
Key facts
| NCT number | NCT00095680 |
|---|---|
| Title | Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma |
| Official title | A 24-week, Open-label Extension Study of the Efficacy, Safety, and Tolerability of Oral SCIO-469 in Treatment of Relapsed Refractory Patients With Multiple Myeloma |
| Lead sponsor | Scios, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | SCIO-469, SCIO-469 and bortezomib |
| Enrollment | 30 |
| Start date | Nov 1, 2004 |
| Completion | Feb 1, 2006 |
| First posted | Nov 8, 2004 |
| Last update posted | Oct 22, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: